These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 11558453)
21. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections]. Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148 [No Abstract] [Full Text] [Related]
22. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Scoper SV Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691 [TBL] [Abstract][Full Text] [Related]
23. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia. Lin Y; Su W; Xu Z; Bai Y Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213 [No Abstract] [Full Text] [Related]
24. Clinical application of levofloxacin for severe infections. Tumminello B; Karaniewsky R; Gutierrez-Solana M Chemotherapy; 2006; 52(6):321. PubMed ID: 17047427 [No Abstract] [Full Text] [Related]
25. New generations of quinolones: with particular attention to levofloxacin. Ambrose PG; Owens RC; Quintiliani R; Nightingale CH Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076 [No Abstract] [Full Text] [Related]
26. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Kowalski RP; Karenchak LM; Gordon YJ Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384 [TBL] [Abstract][Full Text] [Related]
27. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates. Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434 [TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
29. [Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections]. Guchev IA; Melekhina EV; Iudenich OV Antibiot Khimioter; 2011; 56(3-4):17-31. PubMed ID: 21913405 [No Abstract] [Full Text] [Related]
30. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363 [TBL] [Abstract][Full Text] [Related]
31. Levofloxacin in the treatment of ventilator-associated pneumonia. Alvarez-Lerma F; Grau S; Alvarez-Beltrán M Clin Microbiol Infect; 2006 May; 12 Suppl 3():81-92. PubMed ID: 16669931 [TBL] [Abstract][Full Text] [Related]
33. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens. Wise R; Andrews JM J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity and durability of a combination of an antibiofilm and an antibiotic against vascular catheter colonization. Mansouri MD; Hull RA; Stager CE; Cadle RM; Darouiche RO Antimicrob Agents Chemother; 2013 Jan; 57(1):621-5. PubMed ID: 23114776 [TBL] [Abstract][Full Text] [Related]
35. Sparfloxacin and levofloxacin. Med Lett Drugs Ther; 1997 Apr; 39(999):41-3. PubMed ID: 9137295 [No Abstract] [Full Text] [Related]
36. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091 [TBL] [Abstract][Full Text] [Related]